Humira In 2023: The $17bn Biosimilar Opportunity

Landmark LOE Looms In US; Several Adalimumab Launches Expected Throughout Year

 
• By Dave Wallace
2023 Dial With Dollar Symbol
Humira’s loss of US exclusivity in 2023 represents the biggest opportunity yet for biosimilars • Source: Shutterstock

More from Biosimilars

More from Products